Acute vulvovaginal candidiasis is a fungal/yeast infection, which is caused by some species of Candida, especially Candida albicans. Increasing cases of vulvovaginal candidiasis can be attributed to ageing, overuse of antibiotics, diabetes, etc. Doctors are involved in prescribing medicines on the basis of their efficiency in controlling acute vulvovaginal candidiasis among the patients.
This report contains market size and forecasts of Acute Vulvovaginal Candidiasis Treatment in Global, including the following market information:
Global Acute Vulvovaginal Candidiasis Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Acute Vulvovaginal Candidiasis Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Clotrimazole Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Acute Vulvovaginal Candidiasis Treatment include Mycovia Pharmaceuticals, Inc, Scynexis, Inc, Basilea Pharmaceutica Ltd, Astellas Pharma Inc, Grupo Ferrer Internacional, S.A, Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc, Cidara Therapeutics, Inc and Amplyx Pharmaceuticals Inc and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Acute Vulvovaginal Candidiasis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Acute Vulvovaginal Candidiasis Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Acute Vulvovaginal Candidiasis Treatment Market Segment Percentages, by Type, 2021 (%)
Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others
Global Acute Vulvovaginal Candidiasis Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Acute Vulvovaginal Candidiasis Treatment Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Acute Vulvovaginal Candidiasis Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Acute Vulvovaginal Candidiasis Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Acute Vulvovaginal Candidiasis Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Acute Vulvovaginal Candidiasis Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Mycovia Pharmaceuticals, Inc
Scynexis, Inc
Basilea Pharmaceutica Ltd
Astellas Pharma Inc
Grupo Ferrer Internacional, S.A
Pacgen Life Science Corporation
NovaDigm Therapeutics, Inc
Cidara Therapeutics, Inc
Amplyx Pharmaceuticals Inc
Pfizer, Inc.